Augmented Reality: Patient Experience Trumps Misconceptions Around Injectables
New global research,2 sponsored by Galderma and released today by leading filler brand Restylane®, has revealed the prevalent societal misconceptions and stereotypes facing the aesthetics industry. Forty percent of respondents admitted they would discourage others from using facial injectables to reduce wrinkles or provide volume. A further 34% said they believed the results of such treatments look fake and unnatural.
Despite holding these views, when the same respondents were presented with a range of images of people who had undergone filler treatments, the data told another story. On average, 4 out of 5 people could not always identify those who had received filler.3 This highlights the common misconceptions about these types of treatments and the results they deliver.
The perceptions surrounding the use of temporary fillers stand in stark contrast to those around the use of permanent beauty treatments such as tattoos, body piercings and dental corrections. Tattoos and body piercings are primarily seen as a positive form of self-expression (30% of respondents agreed for tattoos, and 24% for body piercings). Teeth straightening is viewed by 47% of respondents as a great way to enhance your appearance. Meanwhile, over a third of respondents (35%) believe fillers create unrealistic beauty standards and ideals, while 26% feel they can easily become addictive and 24% say they are an extreme option.
However, Restylane patient feedback data shows that 96% of people who used fillers felt their treatment exceeded expectations,4 and 95% of patients had maintained or enhanced the naturalness of their facial expressions after treatment.5,6
“This new research by Restylane highlights the perception that people are choosing procedures such as fillers because they lack confidence or are going to extremes to get their desired look. But this just isn’t the case! The vast majority of the clients I see are opting for small, subtle changes that will help them create their own look and feel empowered to be the best version of themselves. In my opinion, these people are inherently self-confident, know their own minds and are simply taking control of their own looks.”
DR. LUIZ AVELAR PLASTIC SURGEON BELO HORIZONTE, BRAZIL
|
The prevalence of societal judgements and the impact they have on how people behave are laid bare in the study. Only 11% of respondents said they would be supportive if a friend or family member told them they were considering using fillers. In contrast, according to Restylane patient feedback, 99% of those who have received treatment would recommend Restylane to a friend.4,6
Media leads in debunking misconceptions
The results also reveal that people see the media as more progressive in its views about aesthetic treatments. 27% percent of respondents said the media portrays injectables as empowering, while just 13% would personally describe them this way. Adult Gen Z7 respondents displayed a more open-minded attitude toward aesthetic procedures and were more likely to see treatments of this nature as empowering (19% in this age group agreed versus 13% overall). They were almost three times more likely to feel positively toward fillers than those over 55 years old, only 7% of whom agreed. Younger consumers also feel that people seeking injectable treatments are inherently more confident.
“I’m finding the newer generation is even more open-minded and interested when it comes to injectables. They consider aesthetic treatments to further define and enhance how they look and feel. Given that Restylane studies show that those who use dermal fillers feel overwhelmingly positive about their treatment, we are likely to see more people using them as a means of empowerment.”
STEVEN DAYAN, M.D. FACIAL PLASTIC SURGEON, PROFESSOR AND DIRECTOR OF DENOVA RESEARCH CHICAGO, ILLNOIS, U.S.
|
The research appears ahead of a Restylane product placement spot in new action-comedy film Mafia Mamma, directed by Catherine Hardwicke of Twilight fame and co-starring Toni Collette and Monica Bellucci. Mafia Mamma celebrates female empowerment and sees Toni Collette’s character challenging her comically clueless colleagues and their outdated attitudes about the reasons why women chose to undergo aesthetic treatments. While the film uses humor to highlight these stereotypes and the judgements people make about injectables, the attitudinal study highlights how these real-life judgements are still prevalent in society. Such beliefs have a tangible impact on the way people behave toward those considering fillers.
“We believe in championing everybody’s right to pursue their own beauty ideals. Our research findings are shining a spotlight on some of the misconceptions people have about aesthetic treatments. In this way, we hope to better equip people to make the decision that is right for them, without worrying about external pressures and judgements.”
GERRY MUHLE HEAD OF GLOBAL BUSINESS UNIT, AESTHETICS GALDERMA
|
About Restylane®
Restylane is the original non-animal stabilized hyaluronic acid filler with over 26 years of achievement and over 55 million treatments worldwide. NASHA™ and OBT™ technologies make Restylane the world’s most diverse range of fillers to deliver truly individualized results.4,5
The Restylane portfolio of products includes Restylane, Restylane Lyft™, Restylane Kysse™, Restylane Volyme™, Restylane® Defyne™, Restylane® Refyne™, Restylane® EYELIGHT™, Restylane SKINBOOSTERS™ VITAL and Restylane SKINBOOSTERS™ VITAL LIGHT.
About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information, visit: www.galderma.com.
Footnotes
1 Injectables are aesthetic products which are injected under the skin for a variety of reasons. These include relaxing muscles to alleviate facial wrinkles and folds, or helping contour areas of the face or body, e.g., by restoring volume or adding projection. They often come in the form of products such as botulinum toxin or HA-fillers.
2 Research was carried out by YouGov surveying 9,733 people across the UK, U.S., Canada, Brazil, Germany and Thailand between January 17 and 27, 2023.
3 Respondents were shown six images of people who had used dermal fillers and were asked to indicate if they think the person in the image had used dermal fillers.
4 Andriopoulos B, et al. Presented at: AMWC Monte Carlo, Monaco. 2019.
5 Phillipp-Dormston W, et al. J Cosmet Dermatol. 2020;19:1600–6.
6 Hilton S, et al. Dermatol Surg. 2018;44:261–9.6
7 Adult Gen Z includes those in the 18-24 age bracket.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418006014/en/
Contact information
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Sébastien Cros
Corporate Communications Director
Sebastien.cros@galderma.com
+41 79 529 59 85
Rachel Mooney
Global Franchise Communications
rachel.mooney@galderma.com
+41 76 261 64 41
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alisher Usmanov Wins Legal Case Against Luxembourg’s Largest Media Group, Says Law Firm Rechtsanwälte Steinhöfel12.5.2025 15:43:00 EEST | Press release
A German court has banned Mediahuis Luxembourg S.A., the most important media holding in Luxembourg, from referring to Alisher Usmanov as the owner of the yacht Dilbar. Mediahuis Luxembourg is the leading publishing company in Luxembourg, with such assets as newspapers and online platforms, including Luxemburger Wort, Luxembourg Times and others. On May 5, 2025, the Regional Court of Hamburg ruled that the following statement published by Luxembourg Times was false and prohibited its further publication: “The luxury yacht Dilbar was seized in Hamburg’s harbour in 2022 following Russia’s invasion under EU sanctions. The yacht is owned through a company and trust by Uzbek-Russian billionaire Alisher Usmanov.” The court found the statement to be in violation of Mr. Usmanov’s rights and prohibited its distribution. In the event of non-compliance with the prohibition, Mediahuis may be fined up to €250,000 for each individual offense. Moreover, if such a fine is not enforceable, it may be re
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202512.5.2025 15:23:00 EEST | Press release
Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2025. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €603.4 million, an increase of 8.9% compared to the corresponding data for 2024. All indicators are positive for the period. In the first quarter of 2025 the consolidated EBITDA was €105.3 million compared to €87.3 million in 2024, equal to 17.5% of the turnover. EBIT, from January to March, was €88.7 million (€72.1 million in 2024) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €86.9 million (€73.1 million in 2024), equal to 14.4% of the turnover. The net financial position of the Group on 31 March 2025 is also positive by 537.0 million. The net financial position on 31 December 2024 was positive for €349.1 million. “The close of 2024 and the positive start of 2025,’ said Mario Rizzante, Reply Chairman, ‘reaffirm both the solidity of the Reply model
Adtran boosts DCI capabilities with dynamic AI Network Cloud solution12.5.2025 15:00:00 EEST | Press release
Adtran today announced its new AI Network Cloud (AINC)-interconnect solution, a next-generation fiber networking platform designed to support hyperscalers, federal agencies, SLED organizations and enterprises as they scale AI services. Integrating with Dell’s AI Factory, the technology dynamically adjusts optical networking capacity to meet real-time AI workloads, enabling seamless, high-speed connectivity from data center to data center and from core to edge. By supporting tokenized, sovereign AI networks and dynamic compute allocation, the solution empowers organizations to scale AI initiatives with greater autonomy, control and cost-efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512672981/en/ Adtran’s DCI platform now integrates with Dell’s AI Factory, enabling rapid expansion of AI services. “AI workloads are pushing existing networks to their limits and data center operators need solutions that can scale
HistoSonics Secures First Major Insurance Coverage for Non-Invasive Histotripsy Treatment for Liver Tumors With Blue Cross Blue Shield of Michigan12.5.2025 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison Histotripsy System, today announced that Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network have created a new medical policy for histotripsy of the liver. The policy covers non-thermal histotripsy using the Edison® Histotripsy System for the treatment of primary and metastatic liver tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512714050/en/ HistoSonics Edison Histotripsy System As of February 1, 2025, histotripsy is a reimbursable procedure for the non-invasive mechanical destruction of liver tumors under CPT code 0686T, giving eligible patients in Michigan early access to this groundbreaking, non-invasive, incisionless treatment ahead of the broader policy effective date of July 1, 2025. “Liver tumors are often a leading cause of death for patients with serious cancers, and it’s critical that they have access to safe, effective and non-invasive treatment o
Rochon Genova: Did You Purchase Shares of Aphria Inc. (“Aphria”) After January 29, 2018 and Hold Them Until March 23, 2018 and/or December 3, 2018?12.5.2025 15:00:00 EEST | Press release
A Settlement has been reached in the global class action against Aphria and certain of its former officers and directors regarding alleged misrepresentations made in certain of Aphria’s public disclosures released between January 29, 2018 and December 3, 2018 (the “Class Action”). Aphria and the other Defendants have denied all allegations against them. The Settlement provides for the payment by the Defendants of the total amount of CAD $30,000,000 to resolve the Class Action. The Settlement is a compromise of disputed claims and is not an admission of liability or wrongdoing by the Defendants. The Settlement has been approved by the Ontario Superior Court of Justice. The Court has appointed RicePoint Administration, Inc., d/b/a Verita Global as the Administrator of the Settlement. To be eligible for compensation, Class Members must submit a completed Claim Form to the Administrator no later than August 26, 2025. If you do not file a claim by this deadline, you will be ineligible for c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom